-
Article
c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive disease with a low 5-year overall survival rate of 29.5%. Thus, more effective therapies are in need to prolong survival of AML patients. Mcl-1 is overexpressed in...
-
Article
Open AccessThe combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
About 25% of patients with acute myeloid leukemia (AML) harbor FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD) mutations and their prognosis remains poor. Gilteritinib is a FLT3 inhibitor a...
-
Article
Open AccessTargeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the second most common form of acute leukemia in children. Despite this, very little improvement in survival rates has been ...
-
Article
Open AccessA compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia
Paediatric acute myeloid leukaemia (AML) is a heterogeneous disease characterised by genetics and morphology. The introduction of intensive chemotherapy treatments together with patient stratification and supp...
-
Article
Open AccessInhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia
Venetoclax, an FDA-approved Bcl-2 selective inhibitor for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia (AML), is tolerated well in elderly patients with AML and has good overall res...
-
Article
Open AccessMonozygotic twins with neuroblastoma MS have a similar molecular profile: a case of twin-to-twin metastasis
Fetoplacental neuroblastoma metastasis has been postulated as a mechanism accounting for concordant cases where one twin develops a primary tumour and the second twin manifests the disease without an identifia...
-
Article
Open AccessSimultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia
-
Article
Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo
The survival rate for acute myeloid leukemia remains unacceptably low, in large part owing to resistance to chemotherapy and high rates of relapse. There is an urgent need to develop new therapeutic modalities...
-
Article
Open AccessAn unexpected protein interaction promotes drug resistance in leukemia
The overall survival of patients with acute myeloid leukemia (AML) is poor and identification of new disease-related therapeutic targets remains a major goal for this disease. Here we show that expression of M...
-
Article
Open AccessInhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
Acute myeloid leukemia (AML) is a serious disease. The 5-year survival rates remain frustratingly low (65% for children and 26% for adults). Resistance to frontline chemotherapy (usually cytarabine) often deve...
-
Article
Open AccessMechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells
Acute myeloid leukemia (AML) continues to be a challenging disease to treat, thus new treatment strategies are needed. In this study, we investigated the antileukemic effects of ATR inhibition alone or combine...
-
Article
Open AccessCHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells
Acute myeloid leukemia (AML) remains a difficult disease to treat and requires new therapies to improve treatment outcome. Wee1 inhibitors have been used to prevent activation of the G2 cell cycle checkpoint, ...
-
Article
Knockdown of endogenous myostatin promotes sheep myoblast proliferation
Myostatin (MSTN), is a known negative regulator of myogenesis. Silencing of the function of MSTN could result in increasing muscle mass in mice. To determine the function of endogenous MSTN expression on proli...
-
Chapter
Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy
Following the first description of leukemia in a Down syndrome (DS) child in 1930 (Brewster and Cannon 1930), a national survey in 1957 confirmed that DS individuals had an increased risk of develo** leukemi...
-
Article
Immobilization of glucose isomerase and its application in continuous production of high fructose syrup
Bilayer glucose isomerase was immobilized in porousp-trimethylamine-polystyrene (TMPS) beads, through a molecular deposition technique. Some of the factors that influence the activity of immobilized glucose isome...
-
Article
Immobilization of glucose isomerase and its application in continuous production of high fructose syrup
Bilayer glucose isomerase was immobilized in porousp-trimethylaminepolystyrene (TMPS) beads through a molecular deposition technique. Some of the factors that influence the activity of immobilized glucose isomera...
-
Article
Co-immobilization of cellulase and glucose isomerase by molecular deposition technique
Cellulase was immobilized and co-immobilized with glucose isomerase within p-trimethylamine polystyrene beads using a molecular deposition technique. The co-immobilized enzyme system directly converted insolub...
